VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

SABCS 2022 | Biomarkers to help predict response to CDK4/6 inhibitors

Seth Wander, MD, PhD, Massachusetts General Hospital, Boston, MA, discusses the development of new biomarkers that can help predict which patients are most likely to benefit from CDK4/6 inhibitors. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter